

## RECORDATI: PUBLICATION OF THE INFORMATION DOCUMENT RELATING TO MAJOR TRANSACTIONS WITH RELATED PARTIES

Milan, 7<sup>th</sup> October 2020 – Following the press release issued on 1<sup>st</sup> October 2020, please be informed that, pursuant to article 5 of the Regulations approved by Consob Resolution No. 17221 of 12 March 2010, as subsequently modified and integrated, the **Information Document Relating to Major Transactions with Related Parties**, approved by the Board of Directors on 1<sup>st</sup> October 2020 and prepared to illustrate the **reverse merger** by absorption of Rossini Investimenti S.p.A. and Fime S.p.A. into Recordati S.p.A., together with the related favorable opinion expressed by the Committee for Related-Party Transactions, composed of independent Directors, is available to the public, as of today, at the Company's registered office, on the Company's website ([www.recordati.it](http://www.recordati.it), in the area "Investors", section "Shareholders' Meetings – Reverse Merger into Recordati S.p.A. 2020/2021") and on the "1INFO" storage mechanism ([www.1info.it](http://www.1info.it)).

*Recordati, established in 1926, is an international pharmaceutical group, listed on the Italian Stock Exchange (Reuters RECI.MI, Bloomberg REC IM, ISIN IT 0003828271), with a total staff of more than 4,300, dedicated to the research, development, manufacturing and marketing of pharmaceuticals. Headquartered in Milan, Italy, Recordati has operations throughout the whole of Europe, including Russia, Turkey, North Africa, the United States of America, Canada, Mexico, some South American countries, Japan and Australia. An efficient field force of medical representatives promotes a wide range of innovative pharmaceuticals, both proprietary and under license, in a number of therapeutic areas including a specialized business dedicated to treatments for rare diseases. Recordati is a partner of choice for new product licenses for its territories. Recordati is committed to the research and development of new specialties with a focus on treatments for rare diseases. Consolidated revenue for 2019 was € 1,481.8 million, operating income was € 465.3 million and net income was € 368.9 million.*

For further information:

Recordati website: [www.recordati.com](http://www.recordati.com)

Investor Relations

Marianne Tatschke

(39)0248787393

e-mail: [investorelations@recordati.it](mailto:investorelations@recordati.it)

Media Relations

Studio Noris Morano

(39)0276004736, (39)0276004745

e-mail: [norismorano@studionorismorano.com](mailto:norismorano@studionorismorano.com)

RECORDATI INDUSTRIA CHIMICA E FARMACEUTICA S.p.A.

Sede Legale  
VIA M. CIVITALI, 1  
20148 MILANO, ITALIA  
TEL. (39) 0248787.1  
FAX (39) 0240073747

CAPITALE SOCIALE € 26.140.644,50 i.v.  
REG. IMP. MILANO, MONZA, BRIANZA e LODI 00748210150  
CODICE FISCALE/P. IVA 00748210150  
R.E.A. MILANO 401832

Società Soggetta all'attività di Direzione e Coordinamento di Rossini Luxembourg S.à.r.l